[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"infant-conditions\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:infant-conditions":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,85,124,156,179],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":46,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":5},"100569405","advanced-wireless-sensors-for-neonatal-care-in-the-delivery-room-100569405",false,"NCT06693817","Advanced Wireless Sensors for Neonatal Care in the Delivery Room","Advanced Wireless Sensors for Neonatal Care in the Delivery Room: the AWARD Prospective Multicenter International Study","AWARD","Inclusion criteria:\n\n1. Newborns ≥35 weeks (gestational age)\n2. Newborns determined to be clinically stable at delivery\n3. Newborns with no skin abnormalities\n\nExclusion criteria:\n\n1. Newborns ≤ 35 weeks (gestational age)\n2. Newborns determined to not be clinically stable at delivery\n3. Newborns with Skin abnormalities",true,"ALL","35 Weeks","42 Weeks",{"count":22,"type":23},600,"ESTIMATED","INTERVENTIONAL",[26],"NA","The goals of this observational study is to assess whether a new advanced wireless skin sensor vital sign monitoring system can effectively monitor the vital signs of healthy newborn infants (≥ 35 weeks gestational age). The main aims of this Study are to:\n\n1. Assess feasibility\n2. Evaluate safety\n3. Determine accuracy of the wireless monitoring system, compared to the standard of care wired vital sign monitoring system, immediately after delivery and for the first 2h of age in the obstetrical center under unsupervised parents' care. The newborn infants participating in the Study will have both vital sign monitoring systems placed on their chest and limb. Their vital signs will be monitored for 2h consecutively.",[29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45],"Sudden Unexplained Infant Death","Apnea of Newborn","Newborn Morbidity","Newborn Asphyxia","Birth Outcome, Adverse","Birth Asphyxia","Pregnancy Related","Newborn; Vitality","ECG Electrode Site Reaction","Infant ALL","Infant Death","Infant, Newborn, Diseases","Infant Apnea","Infant Conditions","Parents","Delivery Problem for Fetus","Delivery Complication",[47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72],"Delivery Room","Newborn","Neonatal Resuscitation","Wireless Technology","Vital Sign Monitoring","Sudden Unexplained Post-Natal Collapse","SUPC","Obstetrical Center","Obstetrics","Neonate","Birth","Birthing Center","C-Section","Vaginal Delivery","Sensors","Heart Rate (HR)","Respiratory Rate (RR)","Blood Oxygen Saturation (SpO2)","Skin Temperature (Tskin)","Pulse Rate (PR)","International","Low-Income","Middle-Income","High-Income","Golden Hour","Post-Birth","RECRUITING","2026-05-05",{"date":76,"type":77},"2026-05-08","ACTUAL",{"date":79,"type":77},"2025-04-08",{"date":81,"type":23},"2027-12-30",{"name":83,"class":84},"Guilherme Sant'Anna, MD","OTHER",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":18,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":24,"phases":97,"briefSummary":100,"conditions":101,"keywords":104,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100563231","phase-1-pkpd-of-digoxin-in-infants-with-svhd-100563231","NCT06613477","PK\u002FPD of Digoxin in Infants With SVHD","Pharmacokinetics and Pharmacodynamics of Digoxin in Infants With Single Ventricle Heart Disease","Digoxin R01","Inclusion Criteria:\n\n1. Diagnosis of single ventricle congenital heart disease\n2. Status post-surgical or hybrid stage 1 palliation but prior to surgical stage 2 palliation\n3. Age ≤ 30 days of life at time of stage 1 palliation\n4. Age \\\u003C 6 months at time of enrollment\n5. Require treatment with enteral digoxin per their treating medical provider\n6. Informed consent obtained from parent(s) or legal guardian(s)\n\nExclusion Criteria:\n\n1. Gestational age at birth \\\u003C35 weeks\n2. Serum creatinine \\> 2 mg\u002FdL at enrollment\n3. Diagnosis of second degree or higher atrioventricular conduction block at enrollment\n4. Diagnosis of clinically significant sinus bradycardia requiring intervention at enrollment\n5. Known hypersensitivity to digoxin or other forms of digitalis\n6. Extracorporeal life support (i.e., ECMO, dialysis, ventricular assist device) at enrollment\n7. Received digoxin prior to enrollment\n8. Any condition that would make the participant, in the opinion of the investigator, unsuitable for the study","30 Days","6 Months",{"count":96,"type":23},20,[98,99],"PHASE1","PHASE2","The primary participant will be an infant with single ventricle heart disease.\n\nThis is a research study to learn more about how the medication digoxin, which is routinely prescribed to infants and children with heart disease in pediatric cardiac intensive care units is processed by their bodies and how it may help their cardiac function.\n\nThe investigators will collect blood or will collect blood samples when bloodwork is checked as part of regular care (\"opportunistic\"). The investigators will also collect information from medical records.\n\nBeing part of this study will not change treatment plan or medications. The risks of this study include loss of confidentiality and risks associated with having blood drawn. The study team will make every effort to minimize these risks.",[102,42,40,103],"Single-ventricle","Infant, Premature, Diseases",[105,106,107,108,109,110,111,112,113],"Infants","SVD","SVHD","Single Ventricle","Digoxin","Pharmacokinetics","Pharmacodynamics","PK","PD","2026-01-28",{"date":116,"type":77},"2026-01-30",{"date":118,"type":77},"2024-10-10",{"date":120,"type":23},"2026-11-30",{"name":122,"class":84},"Duke University",2,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":132,"minAge":133,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":24,"phases":137,"briefSummary":138,"conditions":139,"keywords":143,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":155},"100555283","providing-an-optimized-and-empowered-pregnancy-for-you-poppy-aim-3-randomized-controlled-trial-100555283","NCT06510075","Providing an Optimized and Empowered Pregnancy for You (POPPY) Aim 3: Randomized Controlled Trial","Providing an Optimized and emPowered Pregnancy for You (PᵌOPPY) Aim 3: Randomized Controlled Trial","P3OPPY","Inclusion Criteria:\n\n* Self Identifies as Non-Hispanic Black\n* Between 16-49 years old\n* Pregnant individuals between 8⁰ - 22⁶ weeks gestational age\n* Live singleton or dichorionic twin gestation\n* Dating sonogram at \\\u003C23 weeks gestation,\n* Area Deprivation Index (ADI) National 4th or 5th Quintile\n* Planning to deliver at UAB Hospital\n* Speaks and writes in English\n* No indication for delivery at the time of enrollment\n\nExclusion Criteria:\n\n* Declines randomization\n* Speaks or writes in languages other than English\n* Currently incarcerated\n* Fetal demise diagnosed prior to enrollment\n* Known major structural chromosomal abnormalities prior to enrollment\n* Participated in POPPY Pilot","FEMALE","16 Years","49 Years",{"count":136,"type":23},400,[26],"The PᵌOPPY study is designed to support the American Heart Association's mission to improve maternal\u002Finfant health outcomes and address inequities in maternal\u002Finfant health care. The P3OPPY Project is one of five projects within the American Heart Association P3 EQUATE Network. The overarching goal of the P3 EQUATE American Heart Association Health Equity Research Network (HERN) is to promote equity in Maternal and Infant Health outcomes by identifying innovative and cost-effective strategies to enhance access to quality health information, care, and experiences during pregnancy, postnatal and postpartum\u002Fpreconception periods, particularly for Black and under-served populations. Collectively, the investigators will collaborate with pregnant and postpartum individuals and their families, hospitals, and communities to discover ways to reduce racism and social problems that contribute to poor health outcomes. In this trial, 400 non-Hispanic Black participants will be randomized to see if 2 promising interventions (digital health interventions and community health workers) reduce adverse pregnancy outcomes.",[140,141,142,42],"Pregnancy Complications","Maternal Distress","Adverse Birth Outcomes",[144,145],"Pregnancy outcomes","Health inequities","2025-08-13",{"date":148,"type":77},"2025-08-17",{"date":150,"type":77},"2024-08-01",{"date":152,"type":23},"2027-01-31",{"name":154,"class":84},"University of Alabama at Birmingham",1,{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":18,"minAge":163,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":24,"phases":167,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":155},"100565400","be-sweet-to-babies-during-nasolaryngoscopy-100565400","NCT06641687","Be Sweet to Babies During Nasolaryngoscopy","Oral Sucrose for Pain Management During Flexible Nasolaryngoscopy","Inclusion Criteria:\n\n* Patient \\\u003C12 months of age;\n* Scheduled for an appointment with Dr. Nikolaus Wolter or Dr. Jennifer Siu, who are Staff Pediatric Otolaryngologists at the Hospital for Sick Children, or Meghan Tepsich, a complex airway Nurse Practitioner at SickKids;\n* Requiring flexible nasolaryngoscopy for diagnostic purposes;\n* Accompanied by caregivers who provided consent.\n\nExclusion Criteria:\n\n* Patient \\>12 months of age\n* Infants \\\u003C37 weeks corrected gestational age\n* Infants with decreased level of consciousness or delayed neuromuscular development with limited pain response\n* Infants who have received acute\u002Furgent \u002Femergent airway assessment such as respiratory distress or a foreign body, etc.\n* Infants who have received topical anesthesia (topical decongestant\u002Fanesthetic spray)\n* Infants with the following conditions, where oral sucrose is contraindicated or ineffective:\n\n  * Carbohydrate intolerance\n  * Decreased level of consciousness or heavy sedation\n  * Absent gag reflex\n  * Non-functional gastrointestinal tract\n  * History of aspiration, tracheoesophageal fistula\n  * Necrotizing enterocolitis\n* Infants whose parents did not consent to enrolling their child in the study, including randomization into either arm of the study due to preference for a given intervention\n* Any other circumstance in which consent for participation in the study was not obtained prior to the scope\n\nInfants will also be excluded from the study if they present with conditions in which FNL is contraindicated:\n\n* Severe respiratory distress\n* Post-palliative systemic artery to pulmonary artery shunt\n* Single ventricle congenital heart disease","1 Month","12 Months",{"count":166,"type":23},60,[26],"The investigators want to know if sugar water containing 24% sucrose is helpful in reducing pain in babies during scopes.",[42],"2025-07-02",{"date":172,"type":77},"2025-07-04",{"date":174,"type":77},"2024-09-23",{"date":176,"type":23},"2025-09-01",{"name":178,"class":84},"The Hospital for Sick Children",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":17,"sex":18,"minAge":187,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":24,"phases":191,"briefSummary":192,"conditions":193,"keywords":195,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":155},"100539850","prevalence-of-fgids-and-probiotics-study-100539850","NCT06309199","Prevalence of FGIDs and Probiotics Study","Center of Excellence in Thai Pediatric Gastroenterology, Hepatology and Immunology","PROOF","Inclusion Criteria:\n\n1. Healthy and term (GA 37-41 weeks) infants\n2. Appropriate weight for age\n3. APGAR score more than 8 at 10 minutes of life\n4. Normal physical examination\n5. Mothers have no previous probiotics use\n\nExclusion Criteria:\n\n1. not willing to anticipate in the study\n2. cannot come to follow-up until 1 year of age","3 Days","1 Year",{"count":190,"type":23},512,[26],"This is a study to evaluate the prevalence of FGIDs in infants using the Thai version of Rome IV diagnostic questionnaire for functional gastrointestinal disorders in infants and evaluate the efficacy of Limosilactobacillus reuteri DSM 17938 to prevent FGIDs in infants.",[194,42],"Functional Gastrointestinal Disorders",[196,197,198,199,200,201],"functional gastrointestinal disorder","colic","regurgitation","constipation","infant","prevalence","2025-06-28",{"date":170,"type":77},{"date":205,"type":77},"2024-03-14",{"date":207,"type":23},"2026-02",{"name":209,"class":84},"Chulalongkorn University"]